Metabolic Syndrome in Rheumatoid Arthritis: An Overlooked Catalyst of Disease Progression

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease typically affecting individuals aged 20 to 50 and is associated with a significantly higher prevalence of metabolic syndrome (MS) compared to the general population. MS represents a cluster of cardiovascular risk factors characterized by insulin resistance and visceral adiposity. This overlap contributes to elevated morbidity and mortality in RA, particularly through shared inflammatory pathways. Adipose tissue is now recognized as a dynamic immunometabolic organ that secretes pro-inflammatory adipokines, amplifying systemic inflammation in RA. A growing body of evidence links MS to poorer functional outcomes in RA, underscoring the importance of targeting MS not only to reduce cardiovascular risk but also to preserve joint function and quality of life. Rheumatologists should actively screen for and manage MS components through lifestyle interventions, pharmacologic strategies, and cardiovascular monitoring. Emerging data also suggest that certain biologic agents may favorably impact metabolic parameters. This underscores the importance of integrated therapeutic strategies combining biologics, lifestyle modification, and cardiovascular monitoring to improve long-term outcomes. In summary, recent advancements in understanding the relationship between MS and RA emphasize the need for comprehensive care addressing the autoimmune, metabolic, and therapeutic aspects of the disease.